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ORIGINAL ARTICLE
Introduction: Patients with lung cancer are sometimes found to 
have respiratory cultures growing Mycobacterium avium complex 
(MAC). This study describes the clinical, pathologic, and radio-
graphic  characteristics of individuals who harbor concomitant lung 
cancer and MAC.
Methods: Retrospective analysis of patients with positive respiratory 
cultures for MAC (370 men, 475 women) and with newly diagnosed 
lung cancer (792 men, 840 women) from 1995 to 2010.
Results: Of the patients with respiratory cultures growing MAC, 
8.6% of men and 6.3% of women had lung cancer. Twenty-five per-
cent of patients with lung cancer and 3% with nonbronchiectatic 
benign lung disease grew MAC from their respiratory cultures. 
Significantly fewer women with both MAC and lung cancer were 
smokers than the control group of women with lung cancer and nega-
tive MAC cultures (68% versus 89%, p < 0.01). Squamous cell car-
cinoma occurred in 40% of women in the MAC/lung cancer group 
versus 28% of women in the lung cancer control group. Peripherally 
located squamous cell carcinomas were found in 71% of the MAC/
lung cancer group versus 40% of the lung cancer control group 
(p = 0.01)
Conclusions: The percentage of smokers among women with both 
MAC and lung cancer was lower than among the lung cancer con-
trol group who did not grow MAC. The presence of MAC in respi-
ratory cultures of lung cancer patients was particularly associated 
with squamous cell carcinomas located in the periphery of the lung. 
Because MAC typically affects distal airways, this possible associa-
tion between MAC infection and lung cancer warrants further study.
Key Words: Mycobacterium avium, Lung cancer, Squamous cell, 
Inflammation, Nonsmokers, Atypical mycobacteria.
(J Thorac Oncol. 2012;7: 1345–1351)
Over the past 20 years, pulmonary infection with Mycobacterium avium complex (MAC) has been increas-
ingly recognized as a common infection in patients with oth-
erwise normal lungs, particularly thin, elderly women, and in 
more traditional hosts such as patients with chronic obstruc-
tive pulmonary disease and other structural lung disease.1,2 
The incidence of pulmonary MAC disease in women in the 
United States has been increasing,1,2 and this parallels the 
increase in lung cancer incidence in women in certain regions 
of the country
.
3 In a recent population-based study of patients 
with pulmonary nontuberculous mycobacterial disease, 6.5% 
of the patients also had lung cancer.4 At our institution, we 
have noted an apparent marked increase in the number of lung 
cancer patients who have been diagnosed with MAC pulmo-
nary infection over the past decade, prompting us to further 
evaluate the nature and significance of a possible association. 
Our goal was to begin the process of investigating whether 
we were simply observing the juxtaposition of two common 
diseases, versus whether lung cancer may predispose to MAC 
infection, and/or whether MAC infection may predispose to 
the development of lung cancer. In the following study, we 
describe some of the clinical, pathologic, and radiographic 
characteristics of individuals with concomitant pulmonary 
MAC infection and lung cancer.
PATIENTS AND METHODS
To identify all patients who had a positive respiratory 
culture for MAC and lung cancer, a retrospective review was 
performed through a comprehensive search of the patient 
databases at Lankenau Medical Center in Wynnewood, 
Pennsylvania from 1995 to 2010. The names and pathology 
records of all patients with a diagnosis of lung cancer were 
retrieved and cross-referenced with a database of all patients 
with at least one positive respiratory culture for MAC; patients 
with both diagnoses were included in the “MAC/lung cancer 
group.” Cultures were obtained from sputum or bronchoscopy 
specimens. Our goal was to include all patients who may have had 
pulmonary MAC infection, including those with low-grade or 
subclinical infection; therefore, we included those with positive 
MAC respiratory cultures, who might be considered to have only 
“colonization” by the American Thoracic Society/Infectious 
Disease Society of America guidelines for the diagnosis of 
pulmonary MAC infection.5 Of the total of 370 men and 475 
women with positive respiratory cultures for MAC, and 792 men 
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and 840 women with lung cancer, we analyzed the 62 patients 
with both diagnoses—the MAC/lung cancer group. Of the 1632 
individuals with lung cancer, 249 (15%) had mycobacterial 
cultures sent. Control groups were comprised of the 95 men and 
92 women with lung cancer who had negative mycobacterial 
cultures sent. Smoking histories for all patients were obtained 
through chart review and, when available, verbal telephone 
questionnaires. A positive smoking history was defined as at 
least a 15 total pack per year smoking history. The protocol used 
in this study was approved by the Main Line Health Institutional 
Review Board (approval number F/N—R09—2814L).
Pathologic subtypes of lung cancer were recorded by 
review of pathology reports. In cases in which the tumor was 
too poorly differentiated to assign a specific lung cancer sub-
type, but was clearly not a small-cell carcinoma, the designa-
tion “non–small-cell lung carcinoma” was assigned.
Lung cancers were classified as central or peripheral, 
based upon review of chest radiographs and computed tomog-
raphy (CT) scans by two blinded pulmonologists. Central 
tumors were defined as those in which the center of mass was 
within the hilar structures, and peripheral tumors as those in 
which the center of mass was within the parenchyma, with no 
contact or minimal contact (in the case of very large tumors) 
with hilar structures.
Statistical analysis was performed using Fisher’s exact 
test with the calculation of a two-tailed p value for all com-
parisons. A p value of 0.05 or less was considered significant. 
Calculations were performed using Graphpad Prism software 
(GraphPad Prism Software, La Jolla, CA).
RESULTS
There was an overall increase in the number of isolates 
of MAC from respiratory cultures at our institution throughout 
the study period from 1995 to 2010. Isolates for MAC far 
exceeded the number of isolates of pulmonary Mycobacterium 
tuberculosis (MTb), which remained low over the same time 
period (Fig. 1), an extension of findings from our institution 
published in 1989.2
 The overall profile of our study population was as fol-
lows: 32 of 370 men (8.6%) and 30 of 475 women (6.3%) with 
MAC isolated from respiratory cultures also had lung cancer 
(Table 1). Conversely, 32 of 127 men (25%) and 30 of 122 
women (25%) with lung cancer had mycobacterial cultures 
that were positive for MAC (Table 2). Overall, there were 792 
men and 840 women with lung cancer in our database; how-
ever, only 249 of 1632 (15%) had mycobacterial cultures sent 
either via sputum sampling or at the time of bronchoscopy 
for the diagnosis of their lung cancer or for the workup of 
pulmonary symptoms. The mean age of men and women in 
the MAC/lung cancer group was 72 years, versus 71 years 
for the lung cancer control group. None of the patients with 
lung cancer had cultures positive for MTb. In a randomly 
selected sample of 66 patients who underwent bronchoscopy 
at our institution for nonbronchiectatic benign lung disease, 
only two patients (3%) had respiratory cultures growing MAC 
(Table 2). The most common diagnoses among this sample 
of 66 patients with benign lung disease were interstitial lung 
disease (26 patients), sarcoidosis (12 patients), and chronic 
obstructive pulmonary disease (9 patients). Of the two patients 
in this sample who did grow MAC, one had Wegener’s granu-
lomatosis and one had cryptogenic organizing pneumonia.
For the 62 patients in the MAC/lung cancer group, 45 
of 62 patients (73%) were diagnosed with MAC and lung can-
cer within 2 months of each other, thus being considered to 
have simultaneous infection and lung cancer. For the remain-
der, 8 of 62 patients (13%) were diagnosed with MAC from  
FIGURE 1. Total number of cases of pulmonary infection caused by MAC and TB at Lankenau Medical Center, 1996–2010. 
MAC, Mycobacterium avium complex; TB, tuberculosis.
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6 months to 3 years before the diagnosis of lung cancer, and 9 
of 62 (14%) were found to have positive MAC cultures at least 
2 months after their diagnosis of lung cancer (Table 3).
Smoking histories were obtainable for 28 of 30 women 
in the MAC/lung cancer group; nine were lifetime nonsmok-
ers (32%), and 19 (68%) were smokers or former smokers. 
For the 92 women in the lung cancer control group with nega-
tive MAC status, 10 (11%) were lifetime nonsmokers and 82 
(89%) were smokers or former smokers (Table 4). The dif-
ference between these two groups is significant (p < 0.01). 
Smoking histories were obtainable for 29 of the 32 men in the 
MAC/lung cancer group: four (14%) were lifetime nonsmok-
ers, and 25 (86%) were smokers or former smokers. For the 
95 men in the lung cancer control group with negative MAC 
status, four were nonsmokers (4%) and 91 (96%) were smok-
ers or former smokers (p = 0.08) (Table 4).
The MAC/lung cancer group was compared with the 
lung cancer control group with respect to the specific patho-
logic subtypes of lung cancer (Fig. 2A and B). For women, the 
percentage of squamous cell cancer was 40% in the MAC/lung 
cancer group versus 28% in the lung cancer control group, 
a trend that did not reach statistical significance. Overall, no 
significant differences were found in the subtypes of lung can-
cer between the two groups.
Because pulmonary MAC infection typically causes 
pathological abnormalities in the more distal airways, we 
reviewed the radiographic location of the squamous cell can-
cers in the MAC/lung cancer group, looking for potential 
concordance with the location of MAC infection. Of the 28 
patients with squamous cell cancer in the MAC/lung cancer 
group, 20 (71%) had peripheral tumors and eight (29%) had 
central tumors. Among the 20 MAC/lung cancer patients 
with peripheral squamous cell tumors, 13 of 20 (65%) were 
diagnosed with MAC and lung cancer simultaneously; of the 
remaining patients, four of seven were diagnosed with MAC 
before the diagnosis of lung cancer. For the 48 patients with 
squamous cell cancer in the lung cancer control group who 
had CT scans available for review, 19 (40%) had peripheral 
tumors and 29 (60%) had central tumors (Figure 3A). This 
propensity for squamous cell cancer in the MAC/lung cancer 
group to occur in peripheral lung tissue, as compared with the 
lung cancer control group, is significant (p = 0.01).
A representative CT scan of one of the patients in our 
study, who had MAC infection and a peripheral squamous 
cell cancer is shown in Figure 3B. As with most of our study 
patients, the MAC culture was obtained during bronchoscopy 
from the same region of the lung as the tumor. Figure 4 is 
a representative pathologic sample from the lung of one of 
our study patients, depicting a region of granulomatous 
inflammation typical of MAC infection immediately adjacent 
to the squamous cell carcinoma.
DISCUSSION
This study is the first to explore the association of 
pulmonary MAC infection and lung cancer through an analysis 
of a large institutional database. Female patients in the MAC/
lung cancer group were more likely to be nonsmokers than 
women with lung cancer and negative mycobacterial cultures. 
This is particularly noteworthy in light of the disproportionate 
percentage of nonsmoking women who develop lung cancer. 
The percentages of nonsmokers in the lung cancer control 
group of this study roughly matched the percentages of 
nonsmokers among lung cancer patients in a previous large 
study conducted in the United States: 7% for men and 15% to 
20% for women.6
Although the higher percentage of the squamous cell 
cancer subtype among women in the MAC/lung cancer group, 
TABLE 1.  Incidence of Lung Cancer Among Patients With 
MAC Infection, Lankenau Medical Center, 1996–2010
No. Men (%) No. Women (%)
MAC+ 370 475
MAC+ and lung cancer 32 (8.6) 30 (6.3)
MAC, Mycobacterium avium complex.
TABLE 2.  Incidence of MAC Infection in Patients With Lung 
Cancer and Benign Pulmonary Disorders
No.  
Men (%)
No.  
Women (%)
Total
Lung cancer 127 122 249
Lung cancer and MAC+ 32 (25) 30 (25) 62 (25)
Benign pulmonary disorder 25 41 66
Benign pulmonary disorder 
and MAC+
2 (8) 0 (0) 2 (3)
MAC, Mycobacterium avium complex.
TABLE 3.  Temporal Relationship Between Diagnosis of MAC 
and Lung Cancer
MAC Diagnosed 
Before Lung  
Cancer
MAC 
Diagnosed After 
Lung  
Cancer
Simultaneous 
Diagnosis of MAC 
and Lung Cancer
Number  
of patients
8 9 45
Percentage  
of total
13 14 73
Duration  
(mean)
6 mos–3 yrs  
(25 mos)
6 mos–4 yrs  
(15 mos)
Within  
2 mos
When diagnosed within 2 mos of each other they were considered “simultaneous.”
MAC, Mycobacterium avium complex.
TABLE 4. Incidence of MAC in Lung Cancer Patients as a 
Function of Smoking History
No.  
Patients
No. Smokers  
(% of Patients)
No. Nonsmokers  
(% of Patients)
Significance 
 (p)
Women MAC+ 28 19 (68) 9 (32) < 0.01
MAC− 92 82 (89) 10 (11)
Men MAC+ 29 25 (86) 4 (14) = 0.08
MAC− 95 91 (96) 4 (4)
MAC, Mycobacterium avium complex.
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as compared with the lung cancer control group, did not reach 
statistical significance (40% versus 28%), patients of either 
sex in the MAC/lung cancer group with squamous cell cancer 
were more likely to have peripheral lung tumors, compared 
with the lung cancer control group (71% versus 40%). Recent 
evidence suggests an increasing tendency for squamous cell 
carcinomas to arise in peripheral lung tissue, as opposed to 
the historical findings of squamous cell carcinomas occurring 
more typically in central airways. In 1996, Quinn et al.7 
published a series demonstrating an increasing percentage of 
peripheral squamous cell tumors as compared with historical 
controls from a 1969 series from the Mayo clinic (43%, 
compared with 31%). This trend is further described in a 2005 
study by Brooks et al.8 who found that 55% of squamous 
cell carcinomas were peripheral in location.9 This shift over 
time in tumor location for squamous cell carcinoma remains 
unexplained. Because MAC pulmonary infection typically 
affects the small bronchi and bronchioles in peripheral 
lung tissue, we postulate that the increasing incidence of 
this infection could be one of the causes for the increasing 
tendency for squamous cell carcinoma to occur in peripheral 
lung tissue.
The possibility of a link between scarring and inflam-
mation from mycobacterial pulmonary infection and eventual 
development of lung cancer has been previously suggested for 
humans and already been established by a number of animal 
studies. For example, pulmonary infection with MTb has long 
been recognized as a risk factor for lung cancer.10,11 A recent 
population cohort study performed in China found an increased 
risk of lung cancer among individuals with tuberculosis.12 In 
a different study, squamous cell metaplasia developed in the 
lungs of 80% of mice chronically infected with MTb, with 
some of the lesions showing evidence of malignant transforma-
tion.13 When cells from chronic tuberculous lung lesions with-
out evidence of malignancy were transplanted into syngeneic 
FIGURE 3. A, Tumor location in patients with squamous cell 
carcinoma with and without pulmonary MAC infection. B, 
Computed tomography scan of study patient with MAC and 
peripheral squamous cell carcinoma. Short arrow indicates 
location of squamous cell carcinoma. Long arrows indicate 
areas of bronchiolitis and nodular bronchiectasis typical of 
MAC infection. MAC, Mycobacterium avium complex.
FIGURE 2. A, Distribution of different histologic subtypes of 
lung cancer in female patients with and without MAC infec-
tion, and (B) in male patients with and without MAC infec-
tion. MAC, Mycobacterium avium complex.
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mice, 20% of the recipients developed squamous cell tumors. 
Epiregulin, an epidermal growth factor known to be critical in 
the development of squamous cell carcinomas, was shown to 
be up-regulated in the lung tissue of mice after 12 months of 
tuberculous infection.13 Furthermore, recent references from 
Japanese literature suggest the association of mycobacterial 
disease with squamous cell carcinoma,14 with these squamous 
cell carcinomas tending to be peripheral in location.15,16
Chronic pulmonary inflammation has been linked to the 
development of lung cancer in patients with idiopathic pulmo-
nary fibrosis, asbestosis, and interstitial lung disease of other 
types.17,18  A variety of studies have shown the association 
between chronic tissue inflammation or infection and eventual 
development of the squamous cell carcinoma pathologic sub-
type in other organ systems.19–27 A recent report described a 
patient with interferon γ receptor 2 deficiency, who developed 
disseminated infection with MAC and other atypical myco-
bacteria and years later developed diffuse squamous cell car-
cinoma of the skin.28
The persistence of mycobacterial organisms in the lung 
over months to years causes stimulation of a proinflammatory 
response that eventually produces extensive damage to 
surrounding lung and bronchiolar tissue.29–32 There is growing 
recognition that chronic inflammatory processes nurture 
developing malignancies in tissues before overt tumors 
are established.33 Local inflammation triggers the release 
of factors that can support the outgrowth of premalignant 
cells.34 Such inflammation-associated immune activation 
may play a role in combating tumorigenesis, but in some 
cases may also promote malignant progression by positively 
selecting for immune escape variants, a process collectively 
referred to as “immunoediting.”35 The immune environment 
associated with chronic inflammation likely contains multiple 
counterbalancing signals including some that are inherently 
immunosuppressive. Therefore, inflammation may facilitate 
tumor progression by creating local immune tolerance.36,37
The retrospective nature of our study does not allow us to 
answer the question of timing, that is, does the onset of pulmo-
nary MAC infection significantly precede the development of 
lung cancer, or does the lung cancer microenvironment create 
a milieu that promotes the growth of MAC infection in adja-
cent tissue? Although positive MAC cultures were obtained 
before the lung cancer diagnosis for some patients in the 
MAC/lung cancer group, most diagnoses were made simulta-
neously, with many of the positive MAC cultures in our study 
having been obtained by bronchoscopy from the same loca-
tion in the lung as that of biopsy-proven tumors. It is possible 
that lung tumors can create a microenvironment that supports 
the establishment of MAC infection. Although tumors usually 
initiate an inflammatory response in their microenvironment, 
the ensuing inflammation is always accompanied by anti-
inflammation activation. It is advantageous for tumor cells 
to suppress the immune system, thereby helping them escape 
immune surveillance. A suppressed immune tumor microen-
vironment thus promotes tumor progression, and potentially 
establishes a permissive microenvironment for opportunistic 
infections such as MAC to take hold and flourish.
In all likelihood, these findings actually underestimate 
the association of pulmonary MAC infection and lung cancer, 
as most specimens obtained for cytological or pathologic anal-
ysis from patients proven to have lung cancer are not sent for 
mycobacterial culture testing, hence the opportunity to diag-
nose subclinical or low-grade infections is lost. Also of note, 
MAC infections frequently cause nodular bronchiectasis, with 
continuing chronic inflammation, even if the actual infec-
tion is eradicated by the patient’s own defense mechanisms or 
through antibiotic treatment. For these reasons, our lung can-
cer control group may have included some patients with prior 
or clinically unapparent pulmonary MAC infections.
Two of the main limitations of this study are the small 
sample sizes, particularly with regard to the MAC/lung cancer 
group and the subgroups of smokers versus nonsmokers within 
this population, and the retrospective nature of the collection 
of data from a single institution. In addition, the incidence 
of squamous cell cancer in our female lung cancer control 
group was somewhat higher than that described in 1999 by the 
Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute’s lung cancer database (28% 
versus 21%),38 allowing for the possibility that larger numbers 
of patients in both study groups may have resulted in a signifi-
cant difference in the squamous cell subtype between groups.
Our study also highlights the need for caution when 
addressing the increasingly common scenarios that unfold 
when MAC pulmonary infection is identified in patients with 
suspected lung cancer. Radiographic differentiation between 
pulmonary MAC infection and lung cancer can be quite chal-
lenging, particularly because both can present as nodules, nod-
ular infiltrates, or even cavitary lesions.39 The array of potential 
adverse outcomes includes unnecessary diagnostic procedures, 
including resectional lung surgery for patients with MAC mas-
querading as lung cancer at one end of the spectrum, versus the 
possibility that establishing a diagnosis of MAC may abort the 
diagnostic workup for patients with coexisting lung cancer at 
the other end of the spectrum. Our observations emphasize that 
FIGURE 4. Lung pathology specimen of study patient 
depicting squamous cell carcinoma (upper arrow) adjacent 
to a region of granulomatous inflammation typical of MAC 
infection (lower arrow). MAC, Mycobacterium avium complex.
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clinicians must have a heightened index of suspicion for pos-
sible coexistent malignancy when MAC is cultured from respi-
ratory specimens in patients with radiographic abnormalities 
that are also compatible with lung cancer. Patient care would 
be similarly impacted if the results of our studies indicate that 
lung tumors establish an environment that promotes MAC 
infection. Given the potential added physiological burden to 
cancer patients faced with fighting a serious pulmonary infec-
tion while undergoing cancer therapy, these patients should be 
carefully monitored for early detection of MAC disease.
CONCLUSIONS
In summary, this study describes some of the clinical, 
pathological, and radiographic characteristics of a group of 
patients with lung cancer who have had MAC cultured from 
respiratory specimens. Statistical proof of association and/or 
causality between MAC pulmonary infection and lung cancer 
is difficult to establish at this point, particularly because the 
actual incidence of pulmonary MAC infection is unknown. 
Although cautious interpretation is warranted, these observa-
tions prompt us to postulate such an association, particularly 
for nonsmoking elderly women and for patients with periph-
eral lung squamous cell carcinomas. The tendency for lung 
cancer and MAC infection to occur in the same patient, either 
simultaneously or sequentially is not without clinical impact; 
such an association can pose significant diagnostic and thera-
peutic challenges. These observations underscore the need for 
further study of the association between pulmonary mycobac-
terial infections and lung cancer.
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